Victoria Llado Canellas
Chief Strategy Officer Laminar Pharma Inc
Degree in Biology and Biochemistry and PhD in Cell Biology by the UIB. Dr. Lladó has completed postdoctoral stays at prestigious international institutions such as the Gastrointestinal Unit of MGH Harvard Medical School (Boston, MA, USA) and the Sanford-Burnham Medical Research Institute (San Diego, CA, USA) and has enjoyed postdoctoral fellowships for the development of the Melitherapy from the Spanish Association Against Cancer, the Ministry of Science and Innovation (Torres Quevedo program) and the Marathon Foundation. She is the author of more than 20 scientific publications. Dr. Lladó joined Laminar Pharma in 2018 as Chief Scientific Officer and relocated to Boston (USA) in February 2021 for the direction of the company’s business, commercial and scientific strategy in the USA.
Seminars
- Innovating Melitherapy as a platform that specifically targets lipids within the cell membrane, offering a unique approach that contrasts with traditional protein-focused drug design
- Using synthetic fatty acids to modify the composition and fluidity of the cell membrane, which interferes with membrane-associated proteins responsible for disease processes like tumor growth
- Sharing MIN-001-1203 trial of 2-hydroxyoleic acid in patients with advanced solid tumors, including malignant glioma, has shown very promising results, highlighting the potential for significant clinical benefit
